Clinical Trial Search

Primary: Response Rate of Patients Who Receive Pre-operative or Palliative Concurrent Radiation w/ Capecitabine to the Breast & at Risk or Involved Regional Lymph Nodes Basins…

Primary: 4-Week Continuous Abstinence Rate: Percentage of Participants Who Remained Abstinent From Week 9 Through Week 12 — 20.2; 27.2; 18.0 percentage of participants — p=0.6337

Primary: Change in Light and Glare Sensitivity as Determined by a Clinical Glare Test (Primary Efficacy Measure) — 51; 12; 1 Participants

Primary: Change in Weight in Pounds — 3.8 percentage of body weight lost

Primary: Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value — 98.2; 98.9; 98.1; 98.1 Percentage of subjects

Primary: Time to First Relapse — 332.0; 290.0; 495.0; 432.0 days — p=0.643

Primary: Number of Participants With Four Fold Rise in HAI Titers or HAI 1:40 and Above in Each Group at D30 — 15; 17 Participants

Primary: Number of Participants Experiencing Stress Hyperglycemia — 7; 5 Participants

Primary: Change in Body Temperature in Children Undergoing MRI Under General Anesthesia (GA)and Change in Room Temperature Before and After MRI — 36.7; 36.3; -0.4; 21.1 celsius…

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — -23.9; -22.8; -17.5 units on a scale — p=<0.001

Primary: 4-month Progression Free Survival (PFS) Rate — 0.059; 0.118 proportion of participants

Primary: Percent of Participants With Restoration of Normal Serum Potassium (S-K) Values (3.5 to 5.0 mmol/L, Inclusive) at the End of the Acute Phase — 77.9 Percentage of…

Primary: Number of Participants With Grades 3 to 5 Non-hematologic Toxicity. — 4; 5 Participants

Primary: Percentage of Participants Achieving American College of Rheumatology Criteria 50% Improvement (ACR50) Response at Month 6 — 38.28; 46.01; 43.78 Percentage of…

Primary: Change in sCD14 From Baseline to Week 25/26 — 41; 92.3 ug/L — p=0.60